Relevance. Diabetes mellitus (DM), oncological and cardiovascular diseases are the main causes of death of patients all around the world. Scientific research proves an increase in the frequency of cancer of some localizations in patients with type 2 diabetes. Data of the risk of prostate cancer (PС) in patients with diabetes is controversial.
The aim of our study was to investigate the risk of PC in patients with type 2 diabetes, to study the clinical characteristics of patients and methods of hypoglycemic therapy (HGT).
Materials and methods. Archival data of patients with diabetes mellitus and cancer for 2012–2017 were used in the work. The reliability of our results was checked with the help of statistical methods.
Results of the study. It was established that PC in patients with type 2 diabetes mellitus is diagnosed with a frequency of 3.3%. Most often prostate cancer is diagnosed in men with obesity (66.7%) at the age of 60–70 years (50.0%), with a duration of DМ 10–15 years (33.3%), moderate severity (66.7%), with decompensation (75.0%). There was no detectable influence of HGT on the frequency of PC. There isn`t risk of PC in patients with type 2 diabetes [OR=0.95 CI (0.53–1.70), p<0.001].
Conclusions. Patients with type 2 diabetes do not have an increased risk of developing PC. Decompensation of diabetes mellitus and obesity are factors of predispositions to PC in men with type 2 diabetes. The reliable effect of the HGT on the incidence of prostate cancer was not confirmed.